Literature DB >> 21052791

Reduction of blood cholesterol and ischemic injury in the hypercholesteromic rabbits with modified resveratrol, longevinex. [corrected]

Bela Juhasz1, Bela Juhaz, Dipak K Das, Attila Kertesz, Akos Juhasz, Rudolf Gesztelyi, Balazs Varga.   

Abstract

The present study examined the efficacy of using longevinex, a commercially available resveratrol formulation, to lower blood cholesterol in hypercholesteromic rabbits. New Zealand white rabbits were randomly divided into two groups (n = 6 per group), one group was given high cholesterol diet for 3 months while the other group fed regular diet served as control. The high cholesterol diet fed group was further subdivided into two groups (n = 6 per group), one group was given longevinex resveratrol while the other group given vehicle only served as control. Longevinex was given by gavaging up to a period of 6 months. Longevinex-treated rabbits exhibited lowering of plasma cholesterol level. Inhibition of arterial plaque formation was noticed even after 1 month. Longevinex-treated hearts demonstrated improved ventricular recovery when isolated working hearts were subjected to 30 min of ischemia followed by 2 h of reperfusion. Aortic flow and developed pressure during post-ischemic reperfusion period were significantly higher for the longevinex-treated hearts compared to those in control group of hearts. Myocardial infarct size was also lower in the treated group compared to that for the untreated group. These results indicate cholesterol-lowering ability of longevinex, which appears to reflect in its ability to protect the hypercholesteromic hearts from ischemic reperfusion injury.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21052791     DOI: 10.1007/s11010-010-0615-2

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  15 in total

1.  Grape polyphenols exert a cardioprotective effect in pre- and postmenopausal women by lowering plasma lipids and reducing oxidative stress.

Authors:  Tosca L Zern; Richard J Wood; Christine Greene; Kristy L West; Yanzhu Liu; Dimple Aggarwal; Neil S Shachter; Maria Luz Fernandez
Journal:  J Nutr       Date:  2005-08       Impact factor: 4.798

2.  Polyphenols stimulate AMP-activated protein kinase, lower lipids, and inhibit accelerated atherosclerosis in diabetic LDL receptor-deficient mice.

Authors:  Mengwei Zang; Shanqin Xu; Karlene A Maitland-Toolan; Adriana Zuccollo; Xiuyun Hou; Bingbing Jiang; Michel Wierzbicki; Tony J Verbeuren; Richard A Cohen
Journal:  Diabetes       Date:  2006-08       Impact factor: 9.461

Review 3.  Resveratrol in cardioprotection: a therapeutic promise of alternative medicine.

Authors:  Dipak K Das; Nilanjana Maulik
Journal:  Mol Interv       Date:  2006-02

Review 4.  Resveratrol and red wine, healthy heart and longevity.

Authors:  Dipak K Das; Subhendu Mukherjee; Diptarka Ray
Journal:  Heart Fail Rev       Date:  2010-09       Impact factor: 4.214

5.  Red wine polyphenolics increase LDL receptor expression and activity and suppress the secretion of ApoB100 from human HepG2 cells.

Authors:  Sebely Pal; Nerissa Ho; Carlos Santos; Paul Dubois; John Mamo; Kevin Croft; Emma Allister
Journal:  J Nutr       Date:  2003-03       Impact factor: 4.798

6.  Resveratrol, a unique phytoalexin present in red wine, delivers either survival signal or death signal to the ischemic myocardium depending on dose.

Authors:  Jocelyn Dudley; Samarjit Das; Subhendu Mukherjee; Dipak K Das
Journal:  J Nutr Biochem       Date:  2008-09-11       Impact factor: 6.048

7.  Broccoli: a unique vegetable that protects mammalian hearts through the redox cycling of the thioredoxin superfamily.

Authors:  Subhendu Mukherjee; Hiranmoy Gangopadhyay; Dipak K Das
Journal:  J Agric Food Chem       Date:  2007-12-29       Impact factor: 5.279

8.  Long-term effects of resveratrol supplementation on suppression of atherogenic lesion formation and cholesterol synthesis in apo E-deficient mice.

Authors:  Gyeong-Min Do; Eun-Young Kwon; Hye-Jin Kim; Seon-Min Jeon; Tae-Youl Ha; Taesun Park; Myung-Sook Choi
Journal:  Biochem Biophys Res Commun       Date:  2008-07-09       Impact factor: 3.575

9.  Resveratrol promotes atherosclerosis in hypercholesterolemic rabbits.

Authors:  T Wilson; T J Knight; D C Beitz; D S Lewis; R L Engen
Journal:  Life Sci       Date:  1996       Impact factor: 5.037

10.  Cardioprotection with palm oil tocotrienols: comparision of different isomers.

Authors:  Samarjit Das; Istvan Lekli; Manika Das; Gergo Szabo; Judit Varadi; Bela Juhasz; Istvan Bak; Kalanithi Nesaretam; Arpad Tosaki; Saul R Powell; Dipak K Das
Journal:  Am J Physiol Heart Circ Physiol       Date:  2007-12-14       Impact factor: 4.733

View more
  6 in total

Review 1.  Antioxidant effects of resveratrol in the cardiovascular system.

Authors:  Ning Xia; Andreas Daiber; Ulrich Förstermann; Huige Li
Journal:  Br J Pharmacol       Date:  2016-05-06       Impact factor: 8.739

2.  Unique vascular protective properties of natural products: supplements or future main-line drugs with significant anti-atherosclerotic potential?

Authors:  Mark Slevin; Nessar Ahmed; Qiuyu Wang; Garry McDowell; Lina Badimon
Journal:  Vasc Cell       Date:  2012-04-30

3.  Resveratrol based oral nutritional supplement produces long-term beneficial effects on structure and visual function in human patients.

Authors:  Stuart Richer; Shana Patel; Shivani Sockanathan; Lawrence J Ulanski; Luke Miller; Carla Podella
Journal:  Nutrients       Date:  2014-10-17       Impact factor: 5.717

Review 4.  Nanoformulations of natural products for management of metabolic syndrome.

Authors:  Yasamin Davatgaran Taghipour; Marziyeh Hajialyani; Rozita Naseri; Mahvash Hesari; Pantea Mohammadi; Azzurra Stefanucci; Adriano Mollica; Mohammad Hosein Farzaei; Mohammad Abdollahi
Journal:  Int J Nanomedicine       Date:  2019-07-16

5.  Sexual dimorphism of cardiovascular ischemia susceptibility is mediated by heme oxygenase.

Authors:  Anikó Pósa; Krisztina Kupai; Rudolf Ménesi; Zita Szalai; Renáta Szabó; Zoltán Pintér; György Pálfi; Mariann Gyöngyösi; Anikó Berkó; Imre Pávó; Csaba Varga
Journal:  Oxid Med Cell Longev       Date:  2013-09-17       Impact factor: 6.543

6.  Assessing Colonic Exposure, Safety, and Clinical Activity of SRT2104, a Novel Oral SIRT1 Activator, in Patients with Mild to Moderate Ulcerative Colitis.

Authors:  Bruce E Sands; Shashidhar Joshi; Jonathan Haddad; Johannes M Freudenberg; Deepa Elizabeth Oommen; Ethan Hoffmann; Stewart W McCallum; Eric Jacobson
Journal:  Inflamm Bowel Dis       Date:  2016-03       Impact factor: 5.325

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.